In mammalian cells, vinculin is a membrane-cytoskeletal protein in focal adhesion plaques that is involved in linkage of integrin adhesion molecules to the actincytoskeleton. Vinculin is a cytoskeletal protein associated with cell-cell and cell-matrix junctions, where it is thought to function as one of several interacting proteins involved in anchoring F-actin to the membrane.
Discovered independently by Benny Geiger and Keith Burridge, its sequence is 20%-30% similar to α-catenin, which serves a similar function.
Binding alternately to talin or α-actinin, vinculin's shape and, as a consequence, its binding properties are changed. The vinculin gene occurs as a single copy and what appears to be no close relative to take over functions in its absence. Its splice variant metavinculin (see below) also needs vinculin to heterodimerize and work in a dependent fashion.
Vinculin is a 117-kDa cytoskeletal protein with 1066 amino acids. The protein contains an acidic N-terminal domain and a basic C-terminal domain separated by a proline-rich middle segment. Vinculin consists of a globular head domain that contains binding sites for talin and α-actinin as well as a tyrosine phosphorylation site, while the tail region contains binding sites for F-actin, paxillin, and lipids.
Essentially, there is an 835 amino acid N-terminal head, which is split into four domains. This is linked to the C-terminal tail with a linker region.
The recent discovery of the 3D structure sheds light on how this protein tailors its shape to perform a variety of functions. For example, vinculin is able to control the cell’s motility by simply altering its shape from active to inactive. When in its ‘inactive’ state, vinculin’s conformation is characterized by the interaction between its head and tail domains. And, when transforming to the ‘active’ form, such as when talin triggers binding, the intramolecular interaction between the tail and head is severed. In other words, when talin’s binding sites (VBS) of α-helices bind to a helical bundle structure in vinculin’s head domain, the ‘helical bundle conversion’ is initiated, which leads to the reorganization of the α-helices (α1- α-4), resulting in an entirely new five-helical bundle structure. This function also extends to cancer cells, and regulating their movement and proliferation of cancer to other parts of the body.
Cell spreading and movement occur through the process of binding of cell surface integrin receptors to extracellular matrix adhesion molecules. Vinculin is associated with focal adhesion and adherens junctions, which are complexes that nucleate actin filaments and crosslinkers between the external medium, plasma membrane, and actin cytoskeleton. The complex at the focal adhesions consists of several proteins such as vinculin, α-actin, paxillin, and talin, at the intracellular face of the plasma membrane.
In more specific terms, the amino-terminal of vinculin binds to talin, which, in turn, binds to β-integrins, and the carboxy-terminal binds to actin, phospholipids, and paxillin-forming homodimers. The binding of vinculin to talin and actin is regulated by polyphosphoinositides and inhibited by acidic phospholipids. The complex then serves to anchor actin filaments to the membrane.
The loss of vinculin impacts a variety of cell functions; it disrupts the formation of the complex, and prevents cell adhesion and spreading. The absence of the protein demonstrates a decrease in spreading of cells, accompanied by reduced stress fiber formation, formation of fewer focal adhesions, and inhibition of lamellipodia extension. It was discovered that cells that are deficient in vinculin have growth cones that advance more slowly, as well as filopodia and lamellipoida that were less stable than the wild-type. Based on research, it has been postulated that the lack of vinculin may decrease cell adhesion by inhibiting focal adhesion assembly and preventing actin polymerization. On the other hand, overexpression of vinculin may restore adhesion and spreading by promoting recruitment of cytoskeletal proteins to the focal adhesion complex at the site of integrin binding. Vinculin's ability to interact with integrins to the cytoskeleton at the focal adhesion appears to be critical for control of cytoskeletal mechanics, cell spreading, and lamellipodia formation. Thus, vinculin appears to play a key role in shape control based on its ability to modulate focal adhesion structure and function.
Smooth muscles and skeletal muscles (and probably to a lower extent in cardiac muscle) in their well-differentiated (contractile) state co-express (along with vinculin) a splice variant carrying an extra exon in the 3' coding region, thus encoding a longer isoform meta-vinculin (meta VCL) of ~150KD molecular weight — a protein whose existence has been known since the 1980s. Translation of the extra exon causes a 68- to 79-amino acid acid-rich insert between helices I and II within the C-terminal tail domain. Mutations within the insert region correlate with hereditary idiopathic dilated cardiomyopathy.
The length of the insert in metavinculin is 68 AA in mammals and 79 in frog. Compared metavinculin sequences from pig, man, chicken, and frog, and found the insert to be bipartite: the first part variable and the second highly conserved. Both vinculin isoforms co-localize in muscular adhesive structures, such as dense plaques in smooth muscles, intercalated discs in cardiomyocytes, and costameres in skeletal muscles. Metavinculin tail domain has a lower affinity for the head as compared with the vinculin tail. In case of metavinculin, unfurling of the C-terminal hydrophobic hairpin loop of tail domain is impaired by the negative charges of the 68-amino acid insert, thus requiring phospholipid-activated regular isoform of vinculin to fully activate the metavinculin molecule.
^ abGoldmann WH, Ingber DE (2001). "Intact vinculin protein is Require for control of cell shape, cell mechanics, and rac-Dependent Lamellipodia Formation". Biochemical and Biophysical Research Communications290 (2): 749–755. doi:10.1006/bbrc.2001.6243. PMID11785963.
^Xu W, Baribault H, Adamson ED (1998). "vinculin knockout results in heart and brain defects during embryonic development". Development125 (2): 327–337. PMID9486805.
^ abEzzell RM, Goldmann WH, Wang N, Parashurama N, Parasharama N, Ingber DE (1997). "Vinculin promotes cell spreading by mechanically coupling integrins to the cytoskeleton". Exp. Cell Res.231 (1): 14–26. doi:10.1006/excr.1996.3451. PMID9056408.
^Gingras AR, Vogel KP, Steinhoff HJ, Ziegler WH, Patel B, Emsley J et al. (February 2006). "Structural and dynamic characterization of a vinculin binding site in the talin rod". Biochemistry45 (6): 1805–17. doi:10.1021/bi052136l. PMID16460027.
^Feramisco JR, Smart JE, Burridge K, Helfman DM, Thomas GP (1982). "Co-existence of vinculin and a vinculin-like protein of higher molecular weight in smooth muscle". J. Biol. Chem.257 (18): 11024–31. PMID6809764.
^Witt S, Zieseniss A, Fock U, Jockusch BM, Illenberger S (2004). "Comparative biochemical analysis suggests that vinculin and metavinculin cooperate in muscular adhesion sites". J. Biol. Chem.279 (30): 31533–43. doi:10.1074/jbc.M314245200. PMID15159399.
^Strasser P, Gimona M, Herzog M, Geiger B, Small JV (1993). "Variable and constant regions in the C-terminus of vinculin and metavinculin. Cloning and expression of fragments in E. coli". FEBS Lett.317 (3): 189–94. doi:10.1016/0014-5793(93)81274-4. PMID8425604.
^Hazan RB, Kang L, Roe S, Borgen PI, Rimm DL (December 1997). "Vinculin is associated with the E-cadherin adhesion complex". J. Biol. Chem.272 (51): 32448–53. doi:10.1074/jbc.272.51.32448. PMID9405455.
^Hazan RB, Norton L (April 1998). "The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton". J. Biol. Chem.273 (15): 9078–84. doi:10.1074/jbc.273.15.9078. PMID9535896.
^Mazaki Y, Hashimoto S, Sabe H (March 1997). "Monocyte cells and cancer cells express novel paxillin isoforms with different binding properties to focal adhesion proteins". J. Biol. Chem.272 (11): 7437–44. doi:10.1074/jbc.272.11.7437. PMID9054445.
^"Autoimmunity Links Vinculin to the Pathophysiology of Chronic Functional Bowel Changes Following Campylobacter jejuni Infection in a Rat Model.". Digestive Dieseases and Sciences60 (5): 1195–205. May 2015. doi:10.1007/s10620-014-3435-5. PMID25424202.
Critchley DR (2005). "Cytoskeletal proteins talin and vinculin in integrin-mediated adhesion". Biochem. Soc. Trans.32 (Pt 5): 831–6. doi:10.1042/BST0320831. PMID15494027.
Koteliansky VE, Ogryzko EP, Zhidkova NI, Weller PA, Critchley DR, Vancompernolle K et al. (1992). "An additional exon in the human vinculin gene specifically encodes meta-vinculin-specific difference peptide. Cross-species comparison reveals variable and conserved motifs in the meta-vinculin insert". Eur. J. Biochem.204 (2): 767–72. doi:10.1111/j.1432-1033.1992.tb16692.x. PMID1339348.
Mulligan LM, Gardner E, Telenius H, Ponder BA (1992). "Complementary physical and genetic techniques map the vinculin (VCL) gene on chromosome 10q". Genomics13 (4): 1347–9. doi:10.1016/0888-7543(92)90066-2. PMID1505973.
Turner CE, Burridge K (1989). "Detection of metavinculin in human platelets using a modified talin overlay assay". Eur. J. Cell Biol.49 (1): 202–6. PMID2503380.
Turner CE, Miller JT (1994). "Primary sequence of paxillin contains putative SH2 and SH3 domain binding motifs and multiple LIM domains: identification of a vinculin and pp125Fak-binding region". J. Cell. Sci.107 (6): 1583–91. PMID7525621.
Salgia R, Li JL, Lo SH, Brunkhorst B, Kansas GS, Sobhany ES et al. (1995). "Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL". J. Biol. Chem.270 (10): 5039–47. doi:10.1074/jbc.270.10.5039. PMID7534286.
Johnson RP, Craig SW (1995). "F-actin binding site masked by the intramolecular association of vinculin head and tail domains". Nature373 (6511): 261–4. doi:10.1038/373261a0. PMID7816144.
Hirsch MS, Law LY, Trinkaus-Randall V, Svoboda KK (1995). "The intracellular distribution of vinculin and alpha 2 integrin in epithelial cells and chondrocytes". Scanning16 (5): 275–84. doi:10.1002/sca.4950160306. PMID7994488.
Fausser JL, Ungewickell E, Ruch JV, Lesot H (1994). "Interaction of vinculin with the clathrin heavy chain". J. Biochem.114 (4): 498–503. PMID8276759.
Moiseyeva EP, Weller PA, Zhidkova NI, Corben EB, Patel B, Jasinska I et al. (1993). "Organization of the human gene encoding the cytoskeletal protein vinculin and the sequence of the vinculin promoter". J. Biol. Chem.268 (6): 4318–25. PMID8440716.
Deroanne CF, Colige AC, Nusgens BV, Lapiere CM (1996). "Modulation of expression and assembly of vinculin during in vitro fibrillar collagen-induced angiogenesis and its reversal". Exp. Cell Res.224 (2): 215–23. doi:10.1006/excr.1996.0131. PMID8612698.
Maeda M, Holder E, Lowes B, Valent S, Bies RD (1997). "Dilated cardiomyopathy associated with deficiency of the cytoskeletal protein metavinculin". Circulation95 (1): 17–20. doi:10.1161/01.cir.95.1.17. PMID8994410.
Mazaki Y, Hashimoto S, Sabe H (1997). "Monocyte cells and cancer cells express novel paxillin isoforms with different binding properties to focal adhesion proteins". J. Biol. Chem.272 (11): 7437–44. doi:10.1074/jbc.272.11.7437. PMID9054445.
Hazan RB, Kang L, Roe S, Borgen PI, Rimm DL (1998). "Vinculin is associated with the E-cadherin adhesion complex". J. Biol. Chem.272 (51): 32448–53. doi:10.1074/jbc.272.51.32448. PMID9405455.
Hazan RB, Norton L (1998). "The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton". J. Biol. Chem.273 (15): 9078–84. doi:10.1074/jbc.273.15.9078. PMID9535896.